Business Description
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
Business History
Price Overview
Last updated: Jun 27, 2026 10:06am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -0.67
Total Equity: -$12.09M
Shares: 50,028,000
Total Debt: $86.60M
Cash: $29.03M
EBITDA: -$14.01M
Total Debt: $86.60M
Cash: $29.03M
Revenue: $107.88M
Shares: 50,028,000
Revenue: $107.88M
Revenue: $107.88M
Revenue: $107.88M
Total Equity: -$12.09M
Tax Rate: 5.2%
Equity: -$12.09M
Total Debt: $86.60M
Cash: $29.03M
Current Liabilities: $49.53M
Long-Term Debt: $84.71M
Total Debt: $86.60M
Total Equity: -$12.09M
Shares: 50,028,000
Shares: 50,028,000
CapEx: -$1.16M
Shares: 50,028,000
Stock Price: $0.43
Net Income: -$33.52M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 24, 2026 8:43am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $22.2M | $37.1M | $70.2M | $90.0M | $107.9M |
| Cost of Revenue | $11.7M | $17.8M | $26.3M | $34.9M | $43.4M |
| Gross Profit | $10.6M | $19.2M | $43.9M | $55.1M | $64.4M |
| Operating Expenses | $37.4M | $57.1M | $71.3M | $79.9M | $79.8M |
| Operating Income | -$26.8M | -$37.9M | -$27.3M | -$24.7M | -$15.4M |
| Net Income | -$29.0M | -$44.0M | -$43.1M | -$38.1M | -$33.5M |
| EBITDA | -$24.1M | -$36.4M | -$30.5M | -$22.0M | -$14.0M |
| EPS | $-2.38 | $-2.78 | $-1.66 | $-0.78 | $-0.67 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 8:43am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $58.5M | $15.5M | $22.4M | $46.8M | $29.0M |
| Total Current Assets | $66.6M | $29.1M | $38.2M | $66.9M | $53.4M |
| Total Assets | $75.1M | $119.1M | $129.1M | $157.3M | $148.0M |
| Current Liabilities | $16.4M | $18.3M | $19.5M | $42.7M | $49.5M |
| Long-Term Debt | $7.7M | $34.9M | $35.6M | $51.0M | $84.7M |
| Total Liabilities | $28.2M | $109.8M | $121.9M | $142.5M | $160.0M |
| Total Equity | $46.9M | $9.3M | $7.2M | $14.8M | -$12.1M |
| Retained Earnings | -$244.3M | -$288.3M | -$331.4M | -$369.5M | -$403.0M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 8:43am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$22.5M | -$34.1M | -$21.5M | -$18.5M | -$10.4M |
| Capital Expenditure | $-896,000 | -$4.2M | -$5.0M | -$2.2M | -$1.2M |
| Free Cash Flow | -$23.4M | -$38.3M | -$26.5M | -$20.7M | -$11.6M |
| Acquisitions (net) | $0 | -$25.0M | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $42.5M | -$43.0M | $6.9M | $24.4M | -$17.8M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 6:29am (3h ago)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$111.2M $109.8M – $112.8M
|
$125.2M $123.7M – $127.0M
|
$135.6M $133.9M – $137.5M
|
$162.0M $160.0M – $164.4M
|
| EBITDA |
-$62.1M -$63.0M – -$61.3M
|
-$69.9M -$70.9M – -$69.0M
|
-$75.7M -$76.8M – -$74.7M
|
-$90.4M -$91.7M – -$89.3M
|
| Net Income |
-$32.1M -$36.3M – -$27.3M
|
-$22.5M -$26.9M – -$17.3M
|
-$12.5M -$12.7M – -$12.3M
|
$-500,280 $-509,721 – $-492,257
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 8:43am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +66.6% | +89.4% | +28.3% | +19.8% |
| Gross Profit Growth | +81.9% | +128.6% | +25.5% | +16.9% |
| Operating Income Growth | -41.2% | +27.9% | +9.5% | +37.7% |
| Net Income Growth | -51.9% | +2.1% | +11.7% | +12.0% |
| EBITDA Growth | -51.1% | +16.3% | +27.7% | +36.4% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 6:29am (3h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-18 | OConnell Brendan | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Bednarski Eric | 0.00 | $0.00 | $0 | |
| 2026-03-18 | Bellano John | 20,000.00 | $0.00 | $0 | |
| 2026-03-18 | Bellano John | 65,000.00 | $2.62 | $170,300 | |
| 2026-03-18 | Bellano John | 200,000.00 | $1.47 | $294,000 | |
| 2026-03-18 | McGarrity Michael | 0.00 | $0.00 | $0 | |
| 2026-03-18 | McGarrity Michael | 50,000.00 | $0.00 | $0 | |
| 2026-03-18 | McGarrity Michael | 186,875.00 | $2.62 | $489,613 | |
| 2026-03-18 | McGarrity Michael | 500,000.00 | $1.47 | $735,000 | |
| 2026-03-18 | Sollee Joseph | 20,000.00 | $0.00 | $0 | |
| 2026-03-18 | Sollee Joseph | 65,000.00 | $2.62 | $170,300 | |
| 2026-03-18 | Sollee Joseph | 200,000.00 | $1.47 | $294,000 | |
| 2026-03-18 | KALFUS RON | 12,000.00 | $0.00 | $0 | |
| 2026-03-18 | KALFUS RON | 75,000.00 | $2.62 | $196,500 | |
| 2026-03-18 | KALFUS RON | 100,000.00 | $1.47 | $147,000 | |
| 2026-03-18 | HARDISON DON M | 30,000.00 | $2.62 | $78,600 | |
| 2026-03-18 | HARDISON DON M | 10,000.00 | $2.18 | $21,800 | |
| 2026-03-18 | Siegel Sanford Jay | 10,000.00 | $2.18 | $21,800 | |
| 2026-03-18 | Windels Hilde | 1,000.00 | $0.00 | $0 | |
| 2026-03-18 | Windels Hilde | 30,000.00 | $2.62 | $78,600 |
Narrative Economics
market-narrative step).